RT-GLP1 is an investigational peptide that acts as a triple receptor agonist, engaging the GLP-1, GIP and glucagon receptors simultaneously. It is currently the subject of clinical trials and is not an approved medicine.
Most single-mechanism metabolic peptides act on one receptor. RT-GLP1's research interest stems from the combined activity across three pathways, which preclinical and trial research has examined in the context of appetite signalling, glucose handling and energy expenditure.
Because RT-GLP1 is unlicensed and investigational, it sits firmly in the research-compound category. It should not be confused with approved, prescription-only products, and the research literature remains the appropriate reference point.
Onyx Peptides supplies RT-GLP1 as a lyophilised powder across several vial strengths, each HPLC-verified to at least 99% purity with a batch certificate available on request.
This article is provided for educational and research-reference purposes only. It is not medical advice. All products are supplied strictly for in-vitro laboratory research use, not for human or veterinary consumption.
